Transmission of lupus anticoagulant by allogeneic stem cell transplantation

AUTOR(ES)

Massoud, Mira Romany, William, Basem M., Harrill, Katrina, Cooper, Brenda Wimpfheimer, Lima, Marcos de, Schmaier, Alvin H.

FONTE

Rev. Bras. Hematol. Hemoter.

DATA DE PUBLICAÇÃO

2014-07

RESUMO

Passive transmission of autoimmune diseases by allogeneic stem cell transplantation is rare and is ascribed to passive transfer of memory B-cells from donor to recipient. We hereby report a case of transmission of an asymptomatic lupus anticoagulant from a sibling donor to a recipient of transplantation for secondary acute myeloid leukemia. On pre-harvest evaluation, the sibling donor with no history of bleeding or thrombosis was found to have a lupus anticoagulant. After engraftment, the recipient was found to have a new prolonged activated partial thromboplastin time and was subsequently shown to have a lupus anticoagulant on Day +73 after stem cell transplantation. The recipient remained well with no evidence of bleeding, thrombosis, or graft-versus-host disease and was on a stable dose of tacrolimus at the time the lupus anticoagulant was detected. There was no other identifiable trigger for the appearance of a lupus anticoagulant.

Documentos Relacionados

• Epigenetic therapy in allogeneic hematopoietic stem cell transplantation
• The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain
• Importance of killer immunoglobulin-like receptors in allogeneic hematopoietic stem cell transplantation
• Allogeneic hemopoietic stem cell transplantation using mouse spleen cells fractionated by lectins: in vitro study of cell fractions.
• IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation